苯基6-氯-6-脱氧-beta-D-吡喃葡萄糖苷 | 58622-61-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 苯基6-氯-6-脱氧-beta-D-吡喃葡萄糖苷
• 英文名称: Phenyl 6-chloro-6-deoxy-beta-D-glucopyranoside
• 英文别名: (2S,3S,4S,5R,6S)-2-(chloromethyl)-6-phenoxyoxane-3,4,5-triol
• CAS: 58622-61-0
• 化学式: C₁₂H₁₅ClO₅
• 分子量: 274.7
• InChiKey: BRJPYYRBSYQLEC-RMPHRYRLSA-N

物化性质

• 沸点：
  466.3±45.0 °C(Predicted)
• 密度：
  1.442±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  79.2
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Brain-specific drug delivery
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0218300A2

  公开（公告）日：1987-04-15

  The invention provides compounds adapted for the site-specific/sustained delivery of a centrally acting drug species to the brain having the formula [D-DHC] and the non- toxic pharmaceutically acceptable salts thereof, wherein [D] is a centrally acting drug species containing at least one reactive -OH, -COOH, -SH, -NH- or -NH2 functional group and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine ⇒ pyridinium salt redox carrier comprising a dihydroquinoline or dihydroisoquinoline ring system, a carbon atom of the nitrogen-containing ring portion of said ring system being connected via a bridging group to a reactive -OH, -COOH, -SH, -NH- or -NH2 functional group in the centrally acting drug species. The corresponding quaternary derivatives are also described.

  本发明提供了适用于向脑部定点/持续递送具有式[D-DHC]的中枢作用药物种类的化合物及其无毒药学上可接受的盐，其中[D]是含有至少一个活性-OH、-COOH、-SH、-NH-或-NH2官能团的中枢作用药物种类，[DHC]是还原的、可生物氧化的、二氢吡啶⇒吡啶鎓盐氧化还原载体的脂质形式，该载体包含二氢喹啉或二氢异喹啉环系统，所述环系统含氮环部分的碳原子通过桥基与中枢作用药物种类中的活性-OH、-COOH、-SH、-NH-或-NH2 官能团相连。还描述了相应的季衍生物。
• Pharmaceutical formulations for parenteral use
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0335545A2

  公开（公告）日：1989-10-04

  Aqueous parenteral solutions of drugs which are insoluble or only sparingly'soluble in water and/or which are unstable in water, combined with a hydroxypropyl,hydroxyethyl, glucosyl, maltosyl or maltotriosyl derivative of 3-or γ-cyclodextrin, provide a means for alleviating problems associated with drug precipitation at the injection site and/or in the lungs or other organs following parenteral administration.

  不溶于水或只能少量溶于水和/或在水中不稳定的药物的肠外水溶液与 3-或 γ-环糊精的羟丙基、羟乙基、葡糖基、麦芽糖基或麦芽三糖基衍生物结合使用，可以缓解肠外给药后药物在注射部位和/或肺部或其他器官沉淀的问题。
• BRAIN-SPECIFIC DRUG DELIVERY
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0110955A1

  公开（公告）日：1984-06-20
• EP0539493A4
  申请人：——

  公开号：EP0539493A4

  公开（公告）日：1993-06-02
• TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES
  申请人：BODOR, Nicholas S.

  公开号：EP0539493B1

  公开（公告）日：1997-03-26